Emerging market pressures nudge GSK to settle Indian trade margins row?
This article was originally published in Scrip
Executive Summary
Sales pressure in emerging markets on top of the bribery scandal in China may have weighed on GlaxoSmithKline's decision ahead of some of its multinational peers to "buy peace" with chemists and druggists in India in the ongoing trade margins affair.